CORT Shares Rise as Relacorilant Combo Meets Ovarian Cancer Study Goal [Yahoo! Finance]
Amicus Therapeutics (FOLD) Up 0.1% Since Last Earnings Report: Can It Continue? [Yahoo! Finance]
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025
FOLD's Q4 Earnings Miss, Higher Product Sales Drive Revenue Growth [Yahoo! Finance]
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its price target lowered by analysts at Wells Fargo & Company from $18.00 to $17.00. They now have an "overweight" rating on the stock.